This study showed that daratumumab exhibits non-linear pharmacokinetic characteristics after Intravenous administration. C max increase is in proportion to an increase in dose after initial infusion. However, after subsequent infusions, the C max increase is greater than the dose-proportional increase. The reason for this increase in C max is postulated either due to target mediated saturation or due to a decrease in CD38 containing cells by decreasing tumor burden. This evidence concerns the gene CD38 and neoplasm.